Industry news that matters to you.  Learn more

XDx and LabCorp Enter Into Collaboration and License Agreement to Develop Lupus Flare Predictor Test

XDx, Inc. announced recently that it has entered into a collaboration and license agreement with Laboratory Corporation of America® Holdings (LabCorp) (NYSE: LH) whereby each party will collaborate in marker discovery, and LabCorp will develop and commercialize a diagnostic test to predict flares of systemic lupus erythematosus (SLE). The agreement combines XDx’s autoimmune diagnostics research and discovery experience and SLE blood sample database with LabCorp’s diagnostic development and commercialization resources. Financial terms of the agreement were not disclosed.

LabCorp Clinical Trials, DHMRI Form Strategic Alliance to Offer Specialized Biomarker and Assay Development Services

Esoterix Clinical Trials Services, a division of Laboratory Corporation of America Holdings (LabCorp), today announced a strategic alliance with the David H. Murdock Research Institute (DHMRI) to provide its clients with access to enhanced assay development services. Assays developed at DHMRI for contracted research will be transferred to LabCorp Clinical Trials laboratories worldwide to support global clinical studies. The agreement also provides a mechanism for downstream commercialization of companion diagnostics and other biomarker assays once clinical validation has been established.

BG Medicine Announces FDA Clearance of its Galectin-3 Test for Use in Patients with Chronic HF

BG Medicine, Inc., a U.S.-based life sciences company, announced today that the U.S. Food and Drug Administration has cleared the company’s Galectin-3 test for use in conjunction with clinical evaluation as an aid to assess the prognosis of patients diagnosed with chronic heart failure. This marks the first time the FDA has cleared a test to measure galectin-3 blood levels, and is the first novel cardiac test cleared by the FDA in five years.

Duke, LabCorp Launch ‘Factory’ to Translate Biomarkers into Personalized Medicine Tests

If a factory is where raw components are manufactured and assembled into commercial products, then why not take a similar approach to developing diagnostics to predict disease predisposition and response to drugs?

Duke University and the Laboratory Corporation of America have put their collective expertise together to create just such an enterprise, which they’ve dubbed the Biomarker Factory. The project, announced earlier this month, enjoins Duke University Medical Center’s expertise in biomarker discovery and LabCorp’s capacity to develop laboratory-developed tests from validated biomarkers.